Comparative Pharmacology
Head-to-head clinical analysis: HYDERGINE versus MIGRANAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDERGINE versus MIGRANAL.
HYDERGINE vs MIGRANAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates (Hydergine) are a mixture of dihydrogenated ergot alkaloids that act as non-selective dopamine D1 and D2 receptor agonists and serotonin receptor antagonists. They enhance cerebral blood flow and neuronal metabolism, and modulate neurotransmitter activity.
MIGRANAL (dihydroergotamine mesylate) is an ergot alkaloid with agonist activity at serotonin 5-HT1D and 5-HT1B receptors, leading to vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission, thereby aborting migraine attacks.
1-2 mg orally three times daily.
1 mg intramuscularly at onset of migraine headache; may repeat after 1 hour if needed. Maximum: 2 mg per day and 4 mg per week.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically, steady-state is achieved within 3-5 days.
Terminal elimination half-life ranges from 7 to 10 hours (mean 8.5 hours). Prolonged in renal impairment.
Primarily fecal (80%) via biliary excretion; renal excretion accounts for <10% of unchanged drug.
Primarily hepatic metabolism followed by renal excretion. Approximately 10% excreted unchanged in urine; fecal excretion accounts for <1%.
Category C
Category C
Ergot Alkaloid
Ergot Alkaloid